WallStreetZen

NYSE: MRK
Merck & Co Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MRK past earnings growth

How has MRK's earnings growth performed historically?
Company
-46.73%
Industry
22.33%
Market
96.23%
MRK's earnings have grown slower (3.53% per year) than the US Drug Manufacturers - General industry average (11.67%)
Performance
MRK's earnings have grown slower (3.53% per year) than the US market average (33.21%)
Performance
MRK's earnings growth is slowing down - its growth over the last year (-46.73%) is below its 5-year compound annual rate (3.53%)
Performance

MRK past revenue growth

How has MRK's revenue growth performed historically?
Company
6.29%
Industry
18.11%
Market
42.59%
MRK's revenue has grown slower (4.24% per year) than the US Drug Manufacturers - General industry average (5.44%)
Performance
MRK's revenue has grown slower (4.24% per year) than the US market average (19.59%)
Performance
MRK's revenue growth is accelerating - its growth over the last year (6.29%) is above its 5-year compound annual rate (4.24%)
Performance

MRK earnings and revenue history

Current Revenue
$48.5B
Current Earnings
$5.6B
Current Profit Margin
11.5%
MRK's has demonstrated consistent long-term earnings growth over the past 10 years (136.56%)
Performance

MRK Return on equity

Current Company
19.4%
Current Industry
33.2%
Current Market
23.1%
MRK's Return on Equity (19.4%) shows a company that is not efficient at transforming shareholder equity into returns
Performance

MRK Return on assets

Current Company
6.1%
Current Industry
7.3%
MRK is generating lower Return on Assets (6.1%) than the US Drug Manufacturers - General industry average (7.57%)
Performance

MRK Return on capital employed

Current Company
10.08%
Current Industry
11.7%
MRK has gotten more efficient at generating Return on Capital (10.08%) compared to 3 years ago (8.19%)
Performance

Merck & Earnings & Revenue FAQ

What were MRK's earnings last quarter?

On Invalid Date, Merck & (NYSE: MRK) reported Q2 2021 earnings per share (EPS) of $0.61, up 48.74% year over year. Total Merck & earnings for the quarter were $1.55 billion. In the same quarter last year, Merck &'s earnings per share (EPS) was $1.19.

What was MRK's earnings growth in the past year?

As of Q4 2021, Merck &'s earnings has grown -46.73% year over year. This is 69.06 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 22.33%. Merck &'s earnings in the past year totalled $5.57 billion.

What was MRK's revenue last quarter?

On Invalid Date, Merck & (NYSE: MRK) reported Q2 2021 revenue of $11.40 billion up 21.91% year over year. In the same quarter last year, Merck &'s revenue was $9.35 billion.

What was MRK's revenue growth in the past year?

As of Q4 2021, Merck &'s revenue has grown 6.29% year over year. This is 11.82 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 18.11%. Merck &'s revenue in the past year totalled $48.55 billion.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.